Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Change in Intangibles (2019 - 2023)

Innate Pharma posted quarterly Change in Intangibles of -$2.2 million for Q4 2023, down 259.31% year-on-year from $1.4 million in Q4 2022, and down 259.31% on a QoQ basis from -$598885.2 in Q4 2022.

Innate Pharma (IPHA) has 5 years of Change in Intangibles data on file, last reported at -$2.2 million in Q4 2023.

  • For the quarter ending Q4 2023, Change in Intangibles fell 259.31% year-over-year to -$2.2 million; the trailing twelve-month figure through Dec 2023 stood at -$3.2 million (up 75.87% YoY), and the FY2023 full-year result was -$2.2 million, down 259.31% from the prior year.
  • Change in Intangibles for Q4 2023 stood at -$2.2 million, down from -$598885.2 in the prior quarter.
  • Across five years, Change in Intangibles topped out at -$39741.0 in Q2 2021 and bottomed at -$72.1 million in Q2 2019.
  • The 5-year median for Change in Intangibles is -$6.2 million (2020), against an average of -$21.1 million.
  • The widest annual swing landed in 2021, when Change in Intangibles surged 99.61%; it then plunged 259.31% in 2023.
  • A 5-year view of Change in Intangibles shows it stood at -$71.0 million in 2019, then surged by 82.57% to -$12.4 million in 2020, then surged by 96.29% to -$458732.4 in 2021, then slumped by 30.55% to -$598885.2 in 2022, then slumped by 259.31% to -$2.2 million in 2023.
  • The last three Change in Intangibles figures came in at -$2.2 million (Q4 2023), -$598885.2 (Q4 2022), and -$458732.4 (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 68,980.00
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -2.15 Mn
Dec 31, 2023 -2.15 Mn
Dec 31, 2022 -598,885.20
Dec 31, 2022 -598,885.20
Dec 31, 2021 -458,732.35
Dec 31, 2021 -458,732.35
Jun 30, 2021 -39,740.96
Jun 30, 2021 -39,740.96
Dec 31, 2020 -12.37 Mn
Dec 31, 2020 -12.37 Mn
Jun 30, 2020 -10.25 Mn
Jun 30, 2020 -10.25 Mn
Dec 31, 2019 -70.98 Mn
Dec 31, 2019 -70.98 Mn
Jun 30, 2019 -72.06 Mn
Jun 30, 2019 -72.06 Mn